The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD
This study was designed to evaluate the hypothesis that nebulized budesonide) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with acute exacerbations of COPD (AECOPD).
COPD Acute Exacerbation
|Study Start Date:||January 2003|
|Estimated Study Completion Date:||October 2005|
Patients, hospitalized with AECOPD, were randomized into three groups. Group I received only bronchodilator treatment (BDT), Group II received SC (40 mg prednisolon) plus BDT, and Group III received nebulized budesonide (NB)(1500 mcg qid) plus BDT. Improvement rates in multiple parameters during 10-day hospitalization, and acute exacerbation and re-hospitalization rates within one-month after discharge were compared between the groups.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00274222
|Study Chair:||HAKAN GUNEN, MD||INONU UNIVERSITY PULMONARY MEDICINE|